Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.

Date publication

juillet 2020

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Dr LAKKIS Zaher , Pr BRIGAND Cécile

Tous les auteurs :
Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P, Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M, Elias D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32717180

Résumé

Diagnosis and treatment of colorectal peritoneal metastases at an early stage, before the onset of signs, could improve patient survival. We aimed to compare the survival benefit of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), with surveillance, in patients at high risk of developing colorectal peritoneal metastases.

Référence

Lancet Oncol.. 2020 Jul 24;: